BioLight Life Sciences announced that its controlled–release glaucoma insert provided sustained IOP reduction with a positive safety profile throughout a 12–week phase 1/2a trial.

Inserted by a physician during a 10–minute in–office procedure, the Eye–D VS–101 insert is designed to release latanoprost over a period of 12 months.

The multicenter, exploratory trial compared 3 different doses of the VS–101 insert to once–daily latanoprost eye drops in 77 patients. At 12 weeks, patients who were randomized to receive the most effective insert dose demonstrated a 24% reduction from baseline in mean diurnal IOP. Details regarding dose levels, as well as the device’s material, structure and size were not disclosed.

Most adverse events were deemed mild and transient. No unanticipated adverse events were observed.

"The Eye–D latanoprost insert has now successfully demonstrated effective intraocular pressure lowering for 3 months after subconjunctival placement of the insert in human eyes, and was well tolerated,” said the study’s principle investigator Howard Barnebey, MD. “This innovative insert presents a promising approach to improving therapeutic compliance, bypassing the issues of patients remembering to take medication as well as instilling it in their eyes.”